Oral administration of buparvaquone nanostructured lipid carrier enables in vivo activity against Leishmania infantum

Autor: Lis Marie Monteiro, Raimar Löbenberg, Eduardo José Barbosa, Gabriel Lima Barros de Araujo, Paula Keiko Sato, Edite Kanashiro, Raissa H. de Araujo Eliodoro, Mussya Rocha, Vera Lúcia Teixeira de Freitas, Nikoletta Fotaki, Nádia Araci Bou-Chacra

Publikováno v: Repositório Institucional da USP (Biblioteca Digital da Produção Intelectual)
Universidade de São Paulo (USP)
instacron:USP

Leishmaniasis, a neglected tropical disease, is prevalent in 98 countries with the occurrence of 1.3 million new cases annually. The conventional therapy for visceral leishmaniasis requires hospitalization due to the severe adverse effects of the dru

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b93f0d2996c5a354cccdacf88222e7da
https://doi.org/10.1016/j.ejps.2021.106097